Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806234 · ClinicalTrials.gov registry record · Phase 4
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
A Phase 4 study of Psychotic Disorders, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
- 4
- Study locations
NCT00806234: Completed Phase 4 study of Psychotic Disorders, sponsored by Johns Hopkins University.
NCT00806234 is a Phase 4 study of Psychotic Disorders that has completed, run by Johns Hopkins University. The registered enrollment target is 127 participants, below the 250-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (49% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00806234, a Phase 4 study of Psychotic Disorders, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Aripiprazole or Perphenazine
- DRUG Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
Study Locations (4)
Maryland
- University of Maryland - Baltimore
- Johns Hopkins Hospital - Baltimore
New York
- The Zucker Hillside Hospital - Glen Oaks
North Carolina
- University of North Carolina, Division of Child and Adolescent Psychiatry - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
What the finished NCT00806234 record still lists
NCT00806234 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 250-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Psychotic Disorders appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT00806234 reports a single indexed study location in Maryland, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00806234 about?
NCT00806234 is a clinical study titled "Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics". This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
What is the current status of trial NCT00806234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2009-01. Estimated completion is 2014-03.
What conditions does trial NCT00806234 study?
This clinical trial studies the following conditions: Psychotic Disorders.
What interventions are being tested in trial NCT00806234?
The interventions under investigation include: Metformin (DRUG), Aripiprazole or Perphenazine (DRUG), Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00806234?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00806234 being conducted?
This trial has 4 study locations across Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychotic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00806234's enrollment target sits among peer trials
127 13th of 22 higher than 10 of 22 other Psychotic Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychotic Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Antipsychotic Discontinuation in Alzheimer's Disease
COMPLETED · Phase 4
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Racial Disparities in the Expression of Paranoia
RECRUITING · NA
-
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
RECRUITING · NA
-
A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia